| clinical trial | Q30612 |
| P3098 | ClinicalTrials.gov ID | NCT03692065 |
| P6099 | clinical trial phase | phase III clinical trial | Q42824827 |
| P582 | end time | 2022-11-30 | |
| P921 | main subject | cancer | Q12078 |
| P1050 | medical condition | thrombosis | Q261327 |
| P1132 | number of participants | 1722 | |
| P6153 | research site | Hoffmann-La Roche | Q212646 |
| Curie Institute | Q2451973 | ||
| Léon-Bérard Center | Q2944832 | ||
| hôpital Foch | Q3145155 | ||
| Hôpital Saint-André de Bordeaux | Q16508267 | ||
| Institut Sainte Catherine | Q30273611 | ||
| ??? | Q2945711 | ||
| ??? | Q89798279 | ||
| P8005 | research subject recruitment status | recruiting | Q76649708 |
| P1813 | short name | API-CAT | |
| P859 | sponsor | Assistance Publique – Hôpitaux de Paris | Q2867205 |
| P580 | start time | 2018-10-05 | |
| P8363 | study type | interventional study | Q78089383 |
| P1476 | title | Long-term Treatment of Cancer Associated VTE: Reduced vs Full Dose of Apixaban : API-CAT STUDY for APIxaban Cancer Associated Thrombosis |